European Study Finds Abbott CardioMEMS Sensor Results In Improved Quality Of Life And 44% Reduction In Heart Failure Hospitalizations
Portfolio Pulse from Benzinga Newsdesk
A European study found that Abbott's CardioMEMS sensor led to a 44% reduction in heart failure hospitalizations and improved quality of life for patients. This positive outcome may boost Abbott's reputation in the medical device industry.
May 24, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Abbott's CardioMEMS sensor demonstrated a 44% reduction in heart failure hospitalizations in a European study, potentially increasing demand for the product.
The positive results from the European study directly relate to Abbott's CardioMEMS sensor, which may lead to increased demand for the product. This could result in higher revenues for Abbott and a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100